Literature DB >> 23183533

RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.

Krzysztof Sobczak1, Thurman M Wheeler, Wenli Wang, Charles A Thornton.   

Abstract

Myotonic dystrophy type 1 (DM1) is an RNA dominant disease caused by expression of DM protein kinase (DMPK) transcripts that contain an expanded CUG repeat (CUG(exp)). The toxic mRNA localizes to nuclear foci and sequesters proteins involved in the regulation of alternative splicing, such as, muscleblind-like 1 (MBNL1). Here, we used synthetic short interfering RNAs (siRNAs) to target CUG repeats and test the concept that inhibiting the expression of CUG(exp) RNA can mitigate features of DM1 in transgenic mice. Intramuscular injection and electroporation of siRNA resulted in ~70-80% downregulation of CUG(exp) transcripts. A limited survey of endogenous mouse transcripts that contain nonexpanded CUG or CAG repeats showed that most were not affected, though Txlnb containing (CUG)(9) was significantly reduced. By this strategy, the number and intensity of CUG(exp) nuclear foci were reduced and splicing of MBNL1-dependent exons was improved. These data suggest that the expanded CUG repeats are a potential target for allele-selective RNA interference.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183533      PMCID: PMC3594017          DOI: 10.1038/mt.2012.222

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  33 in total

1.  Structural features of microRNA (miRNA) precursors and their relevance to miRNA biogenesis and small interfering RNA/short hairpin RNA design.

Authors:  Jacek Krol; Krzysztof Sobczak; Urszula Wilczynska; Maria Drath; Anna Jasinska; Danuta Kaczynska; Wlodzimierz J Krzyzosiak
Journal:  J Biol Chem       Date:  2004-08-02       Impact factor: 5.157

2.  Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts.

Authors:  B M Davis; M E McCurrach; K L Taneja; R H Singer; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

3.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.

Authors:  J W Miller; C R Urbinati; P Teng-Umnuay; M G Stenberg; B J Byrne; C A Thornton; M S Swanson
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

4.  Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.

Authors:  C L Liquori; K Ricker; M L Moseley; J F Jacobsen; W Kress; S L Naylor; J W Day; L P Ranum
Journal:  Science       Date:  2001-08-03       Impact factor: 47.728

5.  Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes.

Authors:  C A Thornton; K Johnson; R T Moxley
Journal:  Ann Neurol       Date:  1994-01       Impact factor: 10.422

6.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

7.  Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.

Authors:  Ami Mankodi; Masanori P Takahashi; Hong Jiang; Carol L Beck; William J Bowers; Richard T Moxley; Stephen C Cannon; Charles A Thornton
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

8.  Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.

Authors:  Nicolas Charlet-B; Rajesh S Savkur; Gopal Singh; Anne V Philips; Elizabeth A Grice; Thomas A Cooper
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

9.  MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.

Authors:  Warunee Dansithong; Sharan Paul; Lucio Comai; Sita Reddy
Journal:  J Biol Chem       Date:  2004-11-16       Impact factor: 5.157

Review 10.  Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target.

Authors:  Wlodzimierz J Krzyzosiak; Krzysztof Sobczak; Marzena Wojciechowska; Agnieszka Fiszer; Agnieszka Mykowska; Piotr Kozlowski
Journal:  Nucleic Acids Res       Date:  2011-09-09       Impact factor: 16.971

View more
  45 in total

1.  Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.

Authors:  Alexander Manta; Derek W Stouth; Donald Xhuti; Leon Chi; Irena A Rebalka; Jayne M Kalmar; Thomas J Hawke; Vladimir Ljubicic
Journal:  J Physiol       Date:  2019-01-30       Impact factor: 5.182

2.  Duplex RNAs and ss-siRNAs Block RNA Foci Associated with Fuchs' Endothelial Corneal Dystrophy.

Authors:  Jiaxin Hu; Xiulong Shen; Frank Rigo; Thahza P Prakash; V Vinod Mootha; David R Corey
Journal:  Nucleic Acid Ther       Date:  2019-01-24       Impact factor: 5.486

3.  A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.

Authors:  Kaalak Reddy; Jana R Jenquin; Ona L McConnell; John D Cleary; Jared I Richardson; Belinda S Pinto; Maja C Haerle; Elizabeth Delgado; Lori Planco; Masayuki Nakamori; Eric T Wang; J Andrew Berglund
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-30       Impact factor: 11.205

Review 4.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

Review 5.  Myotonic dystrophy: approach to therapy.

Authors:  Charles A Thornton; Eric Wang; Ellie M Carrell
Journal:  Curr Opin Genet Dev       Date:  2017-04-01       Impact factor: 5.578

6.  Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

Authors:  Darren R Bisset; Ewa A Stepniak-Konieczna; Maja Zavaljevski; Jessica Wei; Gregory T Carter; Michael D Weiss; Joel R Chamberlain
Journal:  Hum Mol Genet       Date:  2015-06-16       Impact factor: 6.150

7.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

8.  Studying a Drug-like, RNA-Focused Small Molecule Library Identifies Compounds That Inhibit RNA Toxicity in Myotonic Dystrophy.

Authors:  Suzanne G Rzuczek; Mark R Southern; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2015-09-28       Impact factor: 5.100

Review 9.  Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Authors:  Samantha LoRusso; Benjamin Weiner; W David Arnold
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

10.  Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models.

Authors:  Ariadna Bargiela; Maria Sabater-Arcis; Jorge Espinosa-Espinosa; Miren Zulaica; Adolfo Lopez de Munain; Ruben Artero
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.